在乙型肝炎e抗原阳性患者完成聚乙二醇干扰素α-2a治疗后，

StephenW

Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients
Authors

    First published: 9 March 2018Full publication history
    DOI: 10.1111/apt.14595  View/save citation
    Cited by (CrossRef): 0 articles Check for updates

    Article has an altmetric score of 1
    Funding Information

    The Handling Editor for this article was Professor Roy Pounder, and it was accepted for publication after full peer-review.
    The authors’ complete affiliations are listed in Appendix 1.

Summary
Background

In the large randomised NEPTUNE study, peginterferon alfa-2a 180 μg/wk for 48 weeks produced higher hepatitis B e antigen (HBeAg) seroconversion rates 24 weeks post-treatment (36%) than a lower dose (90 μg/wk) and/or shorter duration (24 weeks) (range 14%-26%).
Aim

To determine seroconversion rates 5 years after completion of treatment in NEPTUNE.
Methods

HBeAg-positive patients who completed 24 weeks’ follow-up in NEPTUNE (with peginterferon alfa-2a 90 μg/wk × 24 weeks [group 1]; 180 μg/wk × 24 weeks [2]; 90 μg/wk × 48 weeks [3] or 180 μg/wk × 48 weeks [4]) were followed up.
Results

Three hundred and eighty three of the 544 patients in the original study were enrolled in the long-term follow-up study. Many patients (196 overall; more in groups 1-3 than 4) received nucleos(t)ide analogues or immunomodulators during follow-up, and more patients had missing data at year 5 in groups 2 and 4 (48 weeks, 50/112) than in groups 1 and 3 (24 weeks, 23/103), which confounds the planned per-protocol analysis. HBeAg seroconversion rates in groups 1, 2, 3 and 4 at year 5 were 47.5%, 50.7%, 52.2% and 67.1%, respectively, (odds ratio for group 4 versus 1-3: 2.02; 95% CI 1.21, 3.38), using multiple imputation methods for missing measurements.
Conclusion

Seroconversion rates are durable for up to 5 years after completion of peginterferon alfa-2a therapy and, consistent with NEPTUNE, the results suggest that the licensed regimen (180 μg × 48 weeks) is more efficacious for HBeAg-positive patients than a lower dose and/or shorter treatment duration.

StephenW

在乙型肝炎e抗原阳性患者完成聚乙二醇干扰素α-2a治疗后，响应持续长达5年
作者

    首次发表：2018年3月9日完整的出版历史
    DOI：10.1111 / apt.14595查看/保存引文
    引用（CrossRef）：0文章检查更新

    文章的对等评分为1
    资金信息

    本文的处理编辑是Roy Pounder教授，在完全同行评审后被接受发表。
    附录1列出了作者完整的从属关系。

概要
背景

在大型随机NEPTUNE研究中，聚乙二醇干扰素α-2a180μg/周48周在治疗后24周产生更高的乙型肝炎e抗原（HBeAg）血清转化率（36％），而较低剂量（90μg/周）和/或持续时间较短（24周）（范围14％-26％）。
目标

确定NEPTUNE治疗结束5年后的血清转化率。
方法

HBeAg阳性患者在NEPTUNE（聚乙二醇干扰素α-2a90μg/周×24周[组1];180μg/周×24周[2];90μg/周×48周）中完成24周随访[3]或180微克/周×48周[4]）随访。
结果

原始研究中544名患者中的三百八十三名参加了长期随访研究。在随访期间，许多患者（总体上196名;更多1-3组比4）在接受随访期间接受了核苷（酸）类似物或免疫调节剂，并且更多患者在第2组和第4组（48周，50/112 ）比组1和3（24周，23/103），这混淆了计划的每个协议分析。第5，第1,2,3和4组HBeAg血清转换率分别为47.5％，50.7％，52.2％和67.1％（第4组比较比1-3：2.02; 95％CI 1.21,3.38） ，使用多种插补方法进行缺失测量。
结论

在完成聚乙二醇干扰素α-2a治疗后，血清转化率持续达5年，与NEPTUNE一致，结果表明许可方案（180μg×48周）对于HBeAg阳性患者比低剂量更有效， /或更短的治疗持续时间。

StephenW

http://onlinelibrary.wiley.com/doi/10.1111/apt.14595/full

咬牙硬挺

五年以后呢？

StephenW

回复 咬牙硬挺 的帖子

哈哈.
响应率持续长达5年, 五年以后也许响应率有太多其他因素??